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The incidence of acute kidney injury (AKI) following cardiac bypass surgery 
can be as high as 30%1 and even a rise in serum creatinine smaller than the 
criterion for AKI after cardiac surgery is associated with an increased post-
surgical morbidity and mortality2. While the etiology of AKI following surgery is 
multi-factorial and the precise underlying mechanisms remain unclear, acute 
tubular injury is the predominant pathology in severe cases of AKI. Although 
numerous strategies have been investigated to minimize AKI during cardiac 
surgery, there is currently no effective renoprotective intervention in clinical 
use3.  
In this context, remote ischemic preconditioning (RIPC), which refers to 
the phenomenon whereby transient non-lethal episodes of ischemia and 
reperfusion to a remote organ or tissue confer multi-organ protection against a 
sustained episode of ischemia/reperfusion to an organ of interest, may hold 
promise4,5. The results of studies investigating the potential for RIPC, 
performed using transient limb ischemia and reperfusion, to reduce the 
incidence of AKI following cardiac surgery have been inconsistent. It is 
therefore not surprising that the recently published study titled “Effect of 
remote ischemic preconditioning on kidney injury among high-risk patients 
undergoing cardiac surgery: a randomized clinical trial” by Zarbock et al6 in 
the Journal of American Medical Association has attracted significant 
attention. 
 
WHAT DOES THIS IMPORTANT STUDY SHOW?  
This multi-center study by Zarbock et al6 investigated the effect of RIPC on 
AKI in 240 patients undergoing on-pump cardiac bypass surgery. Only 
patients with chronic kidney disease at high-risk of developing AKI (as defined 
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by a Cleveland Clinical Foundation score7 of ≥ 6) were eligible. The RIPC 
protocol comprised of 3 cycles of 5-minute upper arm cuff inflations/deflations. 
The study primary endpoint was the incidence of AKI as defined by the Kidney 
Disease: Improving Global Outcomes (KDIGO) criteria8 within the first 72 
hours. Secondary endpoints included renal replacement therapy (RRT), 
myocardial infarction (MI), stroke, in-hospital and 30-day mortality; duration of 
intensive care unit and hospital courses; and changes in kidney injury 
biomarkers.  
Participants randomized to receive RIPC prior to cardiac surgery 
experienced a 15% absolute risk reduction in the incidence of AKI when 
compared to the non-RIPC sham control. Among secondary endpoints, RIPC 
was associated with a 10% absolute risk reduction in RRT and lower levels of 
AKI biomarkers (Neutrophil Gelatinase-Associated Lipocalin [NGAL] and 
Tissue Inhibitor of MetalloProteinases-2 [TIMP-2] and Insulin-Like Growth 
Factor Binding Protein 7 [IGFBP7]), although there were no differences in the 
incidence of MI, stroke or mortality at 30 days. Finally, although RIPC reduced 
the duration of intensive care unit stay, there was no difference in the overall 
length of hospital stay. 
There are several strengths to the study: (1) this was a multi-center 
study which only included patients at high-risk of AKI (as reflected by a high 
incidence of AKI of 52.5% in the control arm); (2) patients were administered 
volatile anesthesia instead of propofol, given the potential confounding effects 
of the latter on RIPC cardioprotection in the setting of cardiac surgery9,10; and 
(3) investigators attempted to maintain blinding of the treatment allocation by 
using a low cuff inflation sham RIPC protocol.  
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Despite its numerous strengths, there are several minor limitations.  
Firstly, despite using the KDIGO criteria to grade AKI8, Zarbock et al6 used a 
cut-off of 72 hours to include patients with an increase in serum creatinine by 
≥ 0.3mg/dl from baseline rather than 48 hours as specified by the guideline8. 
Secondly, they did not report on the pre-existing use or intra-operative use of 
nitrates11 in each group, an agent which may have the potential to interfere 
with RIPC cardioprotection during cardiac surgery12. Finally, although the 
incidence of AKI was very high in the control arm, the follow-up time for major 
clinical endpoints was relatively short, and a longer duration of follow-up may 
have been more informative. 
 
HOW DOES THIS STUDY COMPARE WITH PRIOR STUDIES?  
Despite intensive investigation the actual mechanisms underlying organ 
protection elicited by limb RIPC remain unclear4,5,13. The current paradigm 
suggests that a blood-borne transferrable protective factor(s) is released in 
response to the limb RIPC stimulus5. The identity of the factor(s) remains 
unknown, although it is believed to be a peptide of less than 30 KiloDaltons in 
size - its release into the blood stream is dependent on an intact neural 
pathway to the RIPC-treated limb5,14. 
The first study to investigate the effect of RIPC on the incidence of AKI 
following cardiac surgery was by Venugopal et al15 in 2010, which reported a 
lower incidence of AKI in patients undergoing CABG±valve surgery. However, 
subsequent studies investigating the potential renoprotective effects of RIPC 
in the setting of cardiac bypass surgery have produced mixed results (Table 
1).  A recent meta-analysis of these randomized clinical trials did show a 
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benefit of RIPC on kidney outcomes following cardiac surgery, although the 
included studies used an array of different kidney outcomes16.  
The positive trial by Zarbock et al6 of 240 patients is the largest study 
to prospectively investigate the effect of RIPC on the incidence of AKI in the 
setting of cardiac surgery, and it was sufficiently powered for this outcome; in 
contrast, many of the previous studies had fewer patients and kidney 
outcomes were not primary endpoints. Zarbock et al6 specifically selected 
patients with chronic kidney disease, a population that would be expected to 
be at highest risk of developing post-surgical AKI, whereas other studies have 
not restricted the study population based on the level of pre-operative kidney 
function. In the study by Zarbock et al6, volatile anesthesia was used instead 
of the intravenous anesthetic, propofol. It has been suggested in one small 72 
patient study that RIPC may not reduce peri-operative myocardial injury 
during cardiac surgery9,10 in the presence of propofol. Whether the use of 
propofol is enough to explain the neutral results observed in some of the past 
studies investigating the effect of RIPC on AKI is not clear, given that there 
appears to be no obvious correlation between the use of propofol and the 
absence of RIPC-associated benefits in prior trials (Table 1).  
Whether the benefits observed in some of the phase II studies can 
translate to an improvement in clinical outcome in larger studies remains to be 
tested. However, the long-awaited ERICCA trial17, announced at the latest 
American College of Cardiology Scientific Session, showed that RIPC did not 
improve one-year clinical outcomes (cardiovascular death, MI, 
revascularization and stroke) in a cohort of 1612 patients. Importantly, RIPC 
had no effect on the incidence of AKI during cardiac surgery (a secondary 
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endpoint). The results of the RIPHeart trial, in which AKI was a component of 
the primary endpoint, are eagerly awaited18.   
 Interestingly, RIPC has been reported to confer renoprotection in 
several other clinical settings including major vascular surgery19,20, elective 
percutaneous coronary intervention for stable coronary artery disease21,22, 
primary PCI for ST-segment elevation myocardial infarction patients23,24, and 
kidney transplantation25, although again not all studies have been positive26,27.  
 
WHAT SHOULD CLINICIANS AND RESEARCHERS DO? 
Strategies to protect against AKI during cardiac surgery have remained 
elusive. RIPC may be a feasible and low-cost therapeutic intervention meeting 
this need that could potentially confer additional neuroprotective and 
cardioprotective benefits. To date, no significant adverse effects have been 
reported with RIPC, and the discomfort associated with cuff inflation is not an 
issue in anesthetized patients.  
Currently, RIPC cannot be routinely recommended for kidney and heart 
protection during cardiac surgery as there is no evidence that it improves 
clinical outcome in this clinical setting. However, the study by Zarbock et al6 
has set the scene for a large scale randomized controlled trial, which 
accounts for patient risk factors and the choice of anesthetic agent, to confirm 
if RIPC can reduce the incidence of AKI and assess whether RIPC can 
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Table 1 Major studies investigating renoprotective effect of RIPC during cardiac surgery  
 




RIPC protocol Anesthesia Result Notes 
Positive studies  
Venugopal et al 
201015 
78 Adult CABG ± 
valve 
 




Reduction in AKI Diabetic patients excluded. 
Secondary renal endpoint 
 
Zimmermann et al 
201128 
118 Adult CABG ± 
valve 
 
Three-5 min arm I/R vs no sham 
 
100% volatile only Reduction in AKI Primary renal endpoint 
Candilio et al 
201512 
178 Adult CABG ± 
valve 
 
Two-5 min arm and leg I/R vs un-inflated 
cuff 
 
85% both volatile 
and propofol 
Reduction in AKI (borderline-significant 
P=0.06) 
Secondary renal endpoint 
Zarbock et al 
20156 
240 Adult CABG ± 
valve 
 
Three-5 min arm I/R vs low inflation 
pressure sham  
 
100% volatile only Reduction in renal biomarkers (NGAL 
and TIMP-2 × IGFBP7), AKI and need 
for dialysis 
Primary renal endpoint 
Neutral studies  
Choi et al 201129 76 Adult valve ± 
CABG 
 
Three-10 min leg I/R vs un-inflated cuff 
 
100% volatile No difference in renal biomarkers 
(cystatin C and NGAL) or AKI 
Primary renal endpoint 
Rahman et al 
201130 




Three-5 min arm I/R vs proper sham RIPC 
protocol 
 
98% volatile No difference in serum Cr at 4 days or 
dialysis  
Secondary renal endpoint 
Young et al 
201231 
96 Adult CABG ± 
valve 
 
Three-5 min arm I/R vs proper sham RIPC 
protocol 
 
Both volatile and 
propofol 
No difference in AKI  Secondary renal endpoint 
Meybohm et al 
201432 
180 Adult CABG ± 
valve 
 
Four-5 min arm I/R vs proper sham RIPC 
protocol 
 
100% propofol No difference in AKI  Secondary renal endpoint 
Gallagher et al 
2014 33 
86 Adult CABG ± 
valve 
 




No difference in serum Cr at 4 days or 
dialysis  
Selected CKD patients with 
low eGFR (<60) 
Primary renal endpoint 
 
 
I/R= Ischemia/Reperfusion; AKI=acute kidney injury; CABG=coronary artery bypass graft; Cr=creatinine; eGFR=estimated glomerular filtration rate; 
ICCF=Intermittent cross-clamp fibrillation; RIPC=remote ischemic preconditioning; CKD=chronic kidney disease 
 
 
 
 
